Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

SABS

+ Watchlist+ Portfolio

SAB Biotherapeutics, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$2.95
52-Week Range
$2.44 – $5.15
Market Cap
$288.28M
P/E (TTM)
—
EPS (TTM)
-1.35
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.38
PEG Ratio
—
Return on Equity
-42.83%
Return on Assets
-25.37%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
7.28
Debt/Equity
0.02
Total Debt
$4.92M
Free Cash Flow
$-28.27M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$189.15M

Market Snapshot

About

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing human polyclonal antibody therapeutics using its proprietary DiversitAb platform. The company genetically engineers cattle to produce fully human antibodies that can target a wide range of infectious diseases, cancer, and autoimmune disorders. SAB Biotherapeutics has developed therapeutic candidates for diseases including COVID-19, influenza, and other emerging infectious threats.